In this article, acoustic cell processing, a unique platform technology that allows for the manipulation of cells with nearly shear-free and low power ultrasonic standing waves, is discussed with its application to cell and gene therapy manufacturing illustrated through case studies.
ENGLEWOOD CLIFFS, N.J., Jan. 10, 2018 /PRNewswire/ -- Dynamk Capital, a life sciences venture capital fund, today announced an exciting new investment in advancing the commercial production of CAR T and immunotherapies by adding FloDesign Sonics to its growing portfolio. Dynamk's portfolio companies provide technologies and services that enable biopharmaceutical companies around the world to develop therapeutics faster and produce them more economically.
Pall Life Sciences, a division of global filtration, separation and purification leader Pall Corporation, has announced that the Cadence Acoustic Separator has won the BioProcess International (BPI) Award for best downstream processing application. Celebrated bi-annually since 2012, the BPI Awards are hosted during the BioProcess International Conference in Boston, MA.
Pall Corporation (NYSE:PLL), a global leader in filtration, separation and purification, announced the signing of an exclusive license for acoustic wave separation (AWS), a disruptive technology from FloDesign Sonics (FDS) for cell culture clarification for both fed-batch and perfusion applications. The AWS technology enables very-high-efficiency continuous removal of the cells in a closed system without centrifugation, thereby streamlining a challenging step in the biologics manufacturing process within a small operating footprint. The technology will complement Pall's industry-leading STAXTM depth filtration products to enable continuous clarification of cell culture, enabling integration of the bioreactor with downstream processing.
When oil and gas are extracted from the earth, water also comes to the surface. Known as produced water, it contains naturally occurring hydrocarbons, salt, bacteria, radioactive material and other compounds, as well as any chemical additives used to ease extraction.
Stanley Kowalski, CEO of FloDesign Sonics, has taken to calling 2015 "the year of the product" for his Wilbraham company, when he will focus on getting his device aimed at upending the manufacturing process for biologic drugs out to as many pharmaceutical firms as possible.
On Thursday, FloDesign Sonics, based in Wilbraham, Mass., announced a $10 million Series A led by Bright Capital. The new round of funding also included investments from Ventry Industries of Springfield, as well a James Waters, the founder of Waters Corp., and Jonathan Fleming of Oxford Biosciences.